ArticlePharmaceuticals (Basel, Switzerland)2023

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.

Wataru Kikushima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.